LRRK2 and Parkinson disease: Using this assay, the authors determined that iPD and LRRK2 PD PBMCs display significantly increased levels of mtDNA defects, and pharmacologic inhibition of LRRK2 kinase activity effectively reduced the level of mtDNA defects in iPD PBMCs to the same levels observed in NHCs [118].